Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Treprostinil in PH-COPD
NCT03496623Phase 3Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- May 2018
- Primary completion
- Oct 2022
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in pulmonary hypertension (PH) comparing Inhaled Treprostinil with Placebo (2 arms). Primary endpoint: Change From Baseline in 6-Minute Walk Distance at 12 weeks. Started May 2018; status: terminated.
02
Drugs
treprostinil
03
Conditions
pulmonary hypertension (PH)
Beyond the preview
Go deeper on NCT03496623.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03496623.